SciSparc to Enact 1-for-9 Reverse Share Split as Outstanding Shares Shrink

An announcement from SciSparc Ltd. ( (SPRC) ) is now available.

SciSparc Ltd., a Nasdaq-listed clinical-stage pharmaceutical developer focused on cannabinoid-based therapeutics, is advancing drug programs targeting Tourette syndrome, Alzheimer’s disease and agitation, autism spectrum disorder, and status epilepticus, while also holding a controlling interest in an e-commerce subsidiary selling hemp seed oil-based products. The company’s portfolio is built around THC and non-psychoactive CBD formulations developed through its majority-owned NeuroThera Labs Inc., positioning it within a niche segment of the neuropsychiatric and neurological therapeutics market.

On March 2, 2026, SciSparc announced it will implement a 1-for-9 reverse share split of its ordinary shares, effective at the market open on March 4, 2026, with the stock continuing to trade on Nasdaq under the ticker SPRC on a split-adjusted basis. Following the split, the number of outstanding ordinary shares will decrease from about 5.09 million to roughly 565,500, without changing shareholders’ proportional ownership aside from rounding of fractional shares and corresponding adjustments to options and warrants, a move that is likely aimed at consolidating the share base and supporting compliance with Nasdaq listing requirements.

More about SciSparc Ltd.

SciSparc Ltd., listed on Nasdaq as SPRC, is a clinical-stage pharmaceutical company operating through its majority-owned subsidiary NeuroThera Labs Inc. The company focuses on developing cannabinoid-based therapies, including THC- and CBD-derived drug candidates for Tourette syndrome, Alzheimer’s disease-related agitation, autism spectrum disorder, and status epilepticus, and also controls a unit selling hemp seed oil products on Amazon.

Average Trading Volume: 1,301,067

Technical Sentiment Signal: Sell

Current Market Cap: $2.41M

See more insights into SPRC stock on TipRanks’ Stock Analysis page.